TY - JOUR
T1 - Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
AU - Torres, Martha
AU - García-García, Lourdes
AU - Cruz-Hervert, Pablo
AU - Guio, Heinner
AU - Carranza, Claudia
AU - Ferreyra-Reyes, Leticia
AU - Canizales, Sergio
AU - Molina, Susana
AU - Ferreira-Guerrero, Elizabeth
AU - Téllez, Norma
AU - Montero-Campos, Rogelio
AU - Delgado-Sánchez, Guadalupe
AU - Mongua-Rodriguez, Norma
AU - Sifuentes-Osornio, Jose
AU - Leon, Alfredo Ponce De
AU - Sada, Eduardo
AU - Young, Douglas B.
AU - Wilkinson, Robert J.
N1 - Publisher Copyright:
Copyright © ERS 2015.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Treatment of persons with latent tuberculosis (TB) infection at greatest risk of reactivation is an important component of TB control and elimination strategies. Biomarkers evaluating the effectiveness of treatment of latent TB infection have not yet been identified. This information would enhance control efforts and assist the evaluation of new treatment regimes. We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact. Participants in each group were randomly assigned to the immediate- or deferred-isoniazid treatment arms. Assays of in vitro interferon (IFN)-γ secretion in response to recombinant Rv1737 and overlapping synthetic peptide pools from various groups of immunodominant proteins were performed. During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p≤0.05). The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy. The in vitro IFN-γ responses to these proteins might represent useful markers to evaluate changes associated with treatment of latent TB infection.
AB - Treatment of persons with latent tuberculosis (TB) infection at greatest risk of reactivation is an important component of TB control and elimination strategies. Biomarkers evaluating the effectiveness of treatment of latent TB infection have not yet been identified. This information would enhance control efforts and assist the evaluation of new treatment regimes. We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact. Participants in each group were randomly assigned to the immediate- or deferred-isoniazid treatment arms. Assays of in vitro interferon (IFN)-γ secretion in response to recombinant Rv1737 and overlapping synthetic peptide pools from various groups of immunodominant proteins were performed. During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p≤0.05). The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy. The in vitro IFN-γ responses to these proteins might represent useful markers to evaluate changes associated with treatment of latent TB infection.
UR - https://www.scopus.com/pages/publications/84930189748
U2 - 10.1183/09031936.00123314
DO - 10.1183/09031936.00123314
M3 - Article
C2 - 25359354
AN - SCOPUS:84930189748
SN - 0903-1936
VL - 45
SP - 473
EP - 482
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 2
ER -